USP10 Pre-design Chimera RNAi
- Known as:
- USP10 Pre-design Chimera RNAi
- Catalog number:
- H00009100-R01
- Product Quantity:
- 10 nmol
- Category:
- -
- Supplier:
- Abno
- Gene target:
- USP10 Pre-design Chimera RNAi
Related genes to: USP10 Pre-design Chimera RNAi
- Gene:
- USP10 NIH gene
- Name:
- ubiquitin specific peptidase 10
- Previous symbol:
- -
- Synonyms:
- UBPO, KIAA0190
- Chromosome:
- 16q24.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-02-01
- Date modifiied:
- 2016-01-15
- Gene:
- USP32 NIH gene
- Name:
- ubiquitin specific peptidase 32
- Previous symbol:
- -
- Synonyms:
- NY-REN-60, USP10
- Chromosome:
- 17q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-05-29
- Date modifiied:
- 2014-11-19
Related products to: USP10 Pre-design Chimera RNAi
Related articles to: USP10 Pre-design Chimera RNAi
- Atrial fibrillation (AF) contributes to cardiovascular morbidity and mortality. Ubiquitin-specific peptidase 10 (USP10) plays a crucial role in numerous cellular processes; however, its particular role in AF remains largely unexplored. In the present study, USP10 expression was assessed in human atrial samples and angiotensin II-treated (Ang II-treated) mouse atrial tissues. An Ang II-induced AF mouse model was employed to investigate the effects of USP10 on atrial remodeling and AF susceptibility. Calcium imaging and patch clamp techniques were used to evaluate USP10's influence on calcium handling and triggered activity. Additionally, RNA sequencing, coimmunoprecipitation, and ubiquitination assays were performed to explore the regulatory interactions between USP10 and NADH:ubiquinone oxidoreductase subunit S1 (NDUFS1). Our findings demonstrate that USP10 is downregulated in atrial tissues from mouse models and patients with AF. USP10 overexpression counteracts Ang II-induced atrial remodeling and reduces AF susceptibility. Furthermore, USP10 contributes to the restoration of mitochondrial function in AF. Mechanistically, USP10 deubiquitinates NDUFS1 at lysine 621, stabilizing NDUFS1 protein levels and mitigating Ang II-induced mitochondrial dysfunction. This study uncovers a critical mechanistic link between USP10 and NDUFS1. Our findings suggest that upregulating USP10 or targeting NDUFS1 degradation could provide an alternative therapeutic strategy to mitigate AF progression and associated cardiovascular risk. - Source: PubMed
Publication date: 2026/08/24
Fu WanrongTian Xiao-XuZhou JianghuaHuang Yu-XuLi HuanWang ZhenyaWei Tong-You WadeLi LiZhao Guo-Jun - Oral submucous fibrosis (OSF) is a chronic, progressive, premalignant disorder with expanding epidemiology, rising annual incidence, and increasing malignant transformation rates. Therefore, elucidating its pathogenesis and establishing early intervention strategies remain urgent priorities. In this study, we evaluated the interplay between USP10 and IL-6 and its potential influence on the development of oral submucous fibrosis. Immunohistochemistry and immunofluorescence were used to examine the correlation among IL-6, USP10, and pathological angiogenesis in OSF clinical samples and mouse models, revealing high IL-6 expression in the inflammatory microvasculature alongside downregulated USP10. Functional experiments on human umbilical vein endothelial cells (HUVECs) in vitro, including administration of recombinant human IL-6, demonstrated that USP10 inhibited angiogenesis, cell migration, and cell proliferation, and that targeting USP10 reversed IL-6-mediated pathological angiogenesis. RNA sequencing further identified differentially expressed genes in HUVECs, while mass spectrometry, western blotting, and co-immunoprecipitation uncovered that USP10 interacts with vascular endothelial growth factor receptor 1 (VEGFR1) and inhibits its ubiquitination, thereby suppressing angiogenesis. Collectively, these findings indicate that IL-6 promotes pathological angiogenesis by suppressing USP10 and its interaction with VEGFR1, thus accelerating OSF progression, and suggest that targeting USP10 may represent a promising mechanism for further investigation in OSF therapy. - Source: PubMed
Li ChunyuHan LingshuangWang ZhenhaoXie YihangXu XiaopingChen QianmingXie Liang - Triple-negative breast cancer (TNBC) is an aggressive subtype lacking effective treatment options, and paclitaxel resistance remains a major clinical challenge. This study investigated the role of VASN in mediating paclitaxel resistance in TNBC by integrating transcriptomic and single-cell RNA sequencing data from public databases and clinical samples. Using paclitaxel-resistant TNBC cell lines (MDA-MB-231R and CAL-51R) and xenograft models, we revealed that VASN was significantly upregulated in resistant TNBC cells and tissues, correlating with poor prognosis. Mechanistically, CEBPB directly bound to the VASN promoter to activate its transcription, and VASN interacted with IGF2BP3 via its LRR domain, recruiting USP10 to deubiquitinate and stabilize IGF2BP3 by suppressing K48-linked polyubiquitination. Stabilized IGF2BP3 enhanced ABCB1 expression through mA-dependent mRNA stabilization, activating the PI3K/AKT pathway and driving paclitaxel resistance. Genetic or pharmacological inhibition of VASN resensitized resistant cells to paclitaxel, and computational drug screening identified Trametinib as a candidate to downregulate VASN. Trametinib synergized with paclitaxel to effectively suppress tumor growth without obvious toxicity in resistant models. In summary, we uncovered a new CEBPB-VASN/IGF2BP3/USP10-ABCB1 axis responsible for paclitaxel resistance in TNBC. Targeting VASN with Trametinib in combination with paclitaxel represents a promising therapeutic strategy to overcome chemoresistance, offering a rationale for precision medicine in resistant TNBC. - Source: PubMed
Publication date: 2026/07/13
Liu HaoLu ZexiuChen MaoshanLi ZhenghangChen JianYang XingyuWan XueyingTu GangLiu ManranTang Lingfeng - Oral squamous cell carcinoma (OSCC) is a prevalent malignancy characterized by high morbidity and poor prognosis, largely due to late-stage diagnosis and limited therapeutic options. The molecular mechanisms underlying OSCC pathogenesis remain incompletely understood, necessitating further investigation to support the development of targeted treatment approaches. - Source: PubMed
Publication date: 2026/07/09
Liu YangYou HuitingJiang QingkunHe FeiZhang XinjianXu ZichenGuo KeWang WenquanLiu NingWu YuehanZou RuiyangQiu Jiaxuan - Lenvatinib is a first-line treatment for advanced hepatocellular carcinoma (HCC), yet the development of resistance constitutes a major therapeutic obstacle. While Ubiquitin-specific peptidase 10 (USP10) has been implicated in cancer progression, its specific role in lenvatinib resistance remains unclear. - Source: PubMed
Publication date: 2026/05/14
Zhong Cheng-RuiQiu ZhiyuTang Ya-JunLin ZhuTang DiWan Yun-LeLi Guo-Lin